Designing the selenium and bladder cancer trial (SELEBLAT), a phase lll randomized chemoprevention study with selenium on recurrence of bladder cancer in Belgium by Goossens, Maria E et al.
STUDY PROTOCOL Open Access
Designing the selenium and bladder cancer trial
(SELEBLAT), a phase lll randomized
chemoprevention study with selenium on
recurrence of bladder cancer in Belgium
Maria E Goossens
1,2*, Frank Buntinx
1,3, Steven Joniau
4, Koen Ackaert
5, Filip Ameye
6, Ignace Billiet
7,
Johan Braeckman
8, Alex Breugelmans
9, Jochen Darras
10, Kurt Dilen
11, Lieven Goeman
12, Eliane Kellen
13,
Bertrand Tombal
14, Siska Van Bruwaene
4, Ben Van Cleyenbreuge
4, Frank Van der Aa
4, Kris Vekemans
10,
Hendrik Van Poppel
4 and Maurice P Zeegers
2,3
Abstract
Background: In Belgium, bladder cancer is the fifth most common cancer in males (5.2%) and the sixth most
frequent cause of death from cancer in males (3.8%). Previous epidemiological studies have consistently reported
that selenium concentrations were inversely associated with the risk of bladder cancer. This suggests that selenium
may also be suitable for chemoprevention of recurrence.
Method: The SELEBLAT study opened in September 2009 and is still recruiting all patients with non-invasive
transitional cell carcinoma of the bladder on TURB operation in 15 Belgian hospitals. Recruitment progress can be
monitored live at http://www.seleblat.org. Patients are randomly assigned to selenium yeast (200 μg/day)
supplementation for 3 years or matching placebo, in addition to standard care. The objective is to determine the
effect of selenium on the recurrence of bladder cancer. Randomization is stratified by treatment centre. A
computerized algorithm randomly assigns the patients to a treatment arm. All study personnel and participants are
blinded to treatment assignment for the duration of the study.
Design: The SELEnium and BLAdder cancer Trial (SELEBLAT) is a phase III randomized, placebo-controlled,
academic, double-blind superior trial.
Discussion: This is the first report on a selenium randomized trial in bladder cancer patients.
Trial registration: ClinicalTrials.gov identifier: NCT00729287
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Introduction
In Belgium, 2159 patients were newly diagnosed with a
primary bladder cancer in 2008. These numbers have been
stable over the last five years. The incidence and mortality
rates increase sharply with age and about two-thirds of
patients are ≥ 65 years old. The mean age of diagnosis is
73 years for men and 74 years for women. In the age
group 45-59 years, the male/female ratio is 3:3, while in
the age group 60-74 years the incidence rates in males are
more than fivefold than the rates in females. The relative
5-year survival is 47% for men and 54% for women [1].
Almost 400,000 bladder cancer cases occurred worldwide
in 2008 [2]. Moreover, in the USA and probably in most
Western countries, bladder cancer is the most expensive
cancer in terms of healthcare expenditure [3] because of
lifetime ongoing cystoscopies. Any reduction in the need
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tant, improves quality of life.
Evidence supporting the use of selenium as a general
cancer preventive agent includes proof from geographical,
animal, in vitro, epidemiological and intervention studies.
High selenium intake in Venezuela is associated with a
reduced cancer risk [4]. In animal models, antitumouri-
genic activity has been observed for metabolites of naturally
occurring forms of selenium such as selenomethionine,
selenocysteine and methylselenocysteine and inorganic
selenium salts, such as selenite and selenate [5,6]. Recent in
vitro studies have demonstrated that selenium may be an
effective chemopreventive and anticancer agent with a
broad spectrum against several human cancer cells (pros-
tate, colon, bladder, lung, liver, ovarian, leukemia). In total,
twenty-eight different selenium compounds have been
reported to have anticancer, chemopreventive or apoptotic
activities [7-9]. Three case-control studies reported an
increased risk of bladder cancer, associated with lower
serum [10] and toenail [10-12] selenium concentrations. A
meta-analysis of bladder cancer incidence in five observa-
tional studies [13-17] found an inverse association with an
overall risk estimate of 0.67 (95% CI 0.46 to 0.97) suggest-
ing a protective effect of higher selenium levels against
bladder cancer [18]. The Nutritional Prevention of Cancer
(NPC) study from Clark in 1996 was the first intervention
study that showed a decrease in the incidence of prostate,
lung and colorectal cancers in the selenium-supplemented
group of older Americans. The effect seemed to be the
strongest in the individuals with the lowest selenium status
(< 123.2 ng/mL) [19,20]. Nevertheless, not all cancer pre-
vention trials indicated reduced cancer risk by selenium
supplementation. The selenium and Vitamin E Cancer Pre-
vention Trial (SELECT) failed to show a benefit of selenium
supplementation in reducing the risk of prostate cancer in
a population of healthy men [21]. The lack of positive effect
of selenium supplementation on the prostate cancer inci-
dence observed in this study may have been due to the dif-
ferent form of selenium used, selenomethionine, compared
to Se-enriched yeast in the NPC study [8,22].
The review of Brinkman et al. [23] and the later studies
of Grossman et al. [24], Altwein et al. [25], Busby et al.
[26] and Amaral et al. [27] suggest that selenium may be
suitable for chemoprevention as well as for treatment. It is
useful to perform a selenium trial in a country such as Bel-
gium where the selenium intake is low due to low soil
selenium content. In the Belgian case control study the
mean blood selenium level in the cases was 78.77 ng/mL
compared with 92.31 ng/mL in the controls [10]. This
contrasts with the patients enrolled in the NPC and the
SELECT trials who had higher initial plasma levels of sele-
nium (113 ng/mL and 135 ng/mL, respectively) [28] and
an intake of approximately 90 μg/day. As selenium is
mainly excreted in the urine, it comes into direct contact
and has prolonged exposure with the bladder mucosa,
making the role as a potential chemoprevention agent bio-
logically plausible, unlike the case in prostate cancer.
The objective of SELEBLAT is to investigate whether
200 μg/day Selenium-yeast, in addition to standard care,
reduces the risk of recurrence for patients with non-
invasive bladder cancer.
Methods
Clinical design
SELEBLAT is a phase III randomized, double-blind, pla-
cebo-controlled, multicentre, academic trial with 200 μg/
day Selenium-yeast supplementation during 3 years with
as u b s e q u e n tf o l l o w - u pp e r i o do f3y e a r sa i m e da tt h e
prevention of recurrence of non-muscle-invasive bladder
cancer (NMIBC). SELEBLAT was initiated by the Depart-
ment of General Practice of the University of Leuven and
the Department of Urology of the University hospitals of
Leuven, Belgium with funding by the Agency for Innova-
tion by Science and Technology Belgium (IWT).
Outcome
The primary endpoint of SELEBLAT is the recurrence-
free interval defined as the time from the date of trial
entry to the date of recurrence in patients with superfi-
cial transitional cell carcinoma of the bladder. A recur-
rence is defined as the new occurrence of a bladder
cancer at the same or at a different site as the index
c a n c e ra n de x c l u d i n gt u m o u r si d e n t i f i e da tt h ef i r s t
cystoscopy at three month. Tumours identified within
the first three months are considered as incompletely
resected primary tumours in patients who were macro-
scopically tumour-free after the first resection.
A secondary endpoint is the progression-free interval
defined as the time from the date of trial entry to the date
of progression. Progression is defined as a recurrence with
an increase in tumour grade from low grade (G1-G2) to
high grade (G3), or an increase in TNM stage, or a new
occurrence of carcinoma in situ (CIS) in the bladder pre-
v i o u s l yf r e ef r o ms u c hl e s i o n s ,o ran e wo c c u r r e n c eo f
multiple tumours following resection of a solitary tumour,
or the need for a cystectomy because of refractory disease.
Eligibility criteria for participants
Men and women, at least 18 years of age, who give
informed consent, are eligible for inclusion in SELE-
BLAT, if they have undergone a transurethral resection
(TUR) of a histologically confirmed transitional cell car-
cinoma of the bladder, stage pTa, pT1 or Carcinoma in
situ (Cis). Primary and second primary tumours are
included. Eligibility and exclusion criteria are:
￿ Men and women, aged above 18 years
￿ Histologically confirmed non-muscle-invasive tran-
sitional cell carcinoma (< pT2): stage pTa, pT1 or
Carcinoma in situ (Cis)
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￿ Able to be randomized within three months after
transurethral resection of the bladder tumour
￿ Must be able to swallow pills
￿ Must agree not to take supplements containing
selenium, apart from the trial medication
￿ Fertile female patients must use effective
contraception
￿ No invasive or metastatic disease (stage pT2 or
above)
￿ No history of any type of malignancy within the
past five years
￿ No other serious medical or psychiatric illness that
would preclude giving informed consent
￿ No known hypersensitivity or adverse reactions to
selenium
￿ N o tt a k i n gm o r et h a n5 0m gs e l e n i u m / d a ya sa
dietary supplement, including multivitamin supple-
ments within the last 30 days
￿ Not concurrently participating or having partici-
pated in any other clinical trial involving a medical,
surgical, nutritional or life-style intervention (unless
no longer receiving the intervention and being in the
follow-up phase)
Participant recruitment
Patients are recruited by the participating urologists of
15 hospitals throughout Belgium (Flanders and Brussels)
from September 2009 to August 2012. All subjects have
to master the Dutch or French language and may be
excluded due to illness, mental sickness or incapacity to
comprehend the questions as evaluated by the treating
clinician. Eligible patients receive oral and written infor-
mation (information brochure) from the research nurse
and sign an informed consent form. The procedures fol-
lowed are in accordance with the ethical standards of
the responsible committee on human experimentation
(institutional and national) and with the Helsinki
Declaration of 1975, as revised in 2008. The study has
been approved by the ethical review board of the Uni-
versity Hospital of Leuven acting as the central ethical
review board, by the trial steering committee and by the
appropriate ethical review boards related to the hospitals
in which it is performed. A Data Safety Monitoring
Board (DSMB), comprised of individuals with expertise
in the areas of medicine and biostatistics, has been
established to serve as an external review committee to
monitor the progress of the study including accrual and
adverse events.
Randomization
Randomization is stratified by treatment centre. Once a
patient is deemed to be eligible for the trial and has
given written consent, a trained research nurse rando-
mizes the patient by using the database. A computerized
algorithm randomly assigns the patients to a treatment
arm. All study personnel and participants are blinded to
treatment assignment for the duration of the study. To
evaluate patient blinding, patients are asked by a ques-
tionnaire to evaluate which treatment they believe they
have received (selenium, placebo, or don’tk n o w ) .I f
patients answer either selenium or placebo, they are
asked to indicate what led to that belief.
Participant follow-up
Study participants are supplied with the study drug and
followed on a bi-annual basis for a period of up to three
years. This follow-up phase entails questionnaire distri-
bution and monitoring for adverse events. Study ques-
tionnaires capture the onset of new illnesses and
symptoms, including potential selenium-related
toxicities.
Investigational medicinal product (IMP)
The active product is selenium (200 μg/day, in the form
of high-selenium yeast, SelenoPrecise from PharmaNord,
Vojens, Denmark). A six-month intake of 200 μgo f
SelenoPrecise yeast increases the plasma selenium levels
on average from a baseline value of (mean ± SD) 92 ±
20 ng/mL to 196 ± 42 ng/mL. The increase of the
plasma selenium level is dose-dependent [29]. Patients
in each study arm received an oral tablet (selenium or
placebo) to be taken daily, in addition to standard care.
Standard care is provided as described by Oosterlinck in
the “Guidelines on diagnosis and treatment of superficial
bladder cancer” [30]. Placebos have been manufactured
to be identical in appearance, smell and taste to the
active agents. They were identical in their composition
except for the active agents. The duration of the treat-
ment in both arms is three years, in absence of concur-
rent illness that prevents further administration of
treatment, an unacceptable adverse event, an unaccepta-
ble toxicity or if a patient decides to withdraw from the
study. Treatment stops if general or specific changes in
the patient’s condition render the patient ineligible for
further treatment in the judgment of the investigator or
the treating physician.
Drug interactions/precautions
There are no known contra-indications, interactions or
precautions for the use of selenium. A few individuals
are allergic to yeast for whom this form of supplement
would clearly be unsuitable, but this is not a common
problem [19]. Known adverse health effects of selenium
concern the synthesis of thyroid hormones (diminished
T3 level), hepatotoxicity, gastrointestinal disturbances,
nail and hair loss and dermatitis. However these symp-
toms have been associated with selenium intakes of
more than 700 μg a day [31].
Safety and toxicity
Data on toxicity of selenium yeast are available from
two animal studies while a number of human
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tion of Se-yeast up to 800 μg/d provides no evidence of
toxicity [19].
In 2008 there was an outbreak of selenium toxicity
(selenosis). The source was identified as a liquid dietary
supplement that contained 200 times the labelled con-
centration of selenium in the form of sodium selenite.
Of 201 cases identified in ten states in the US, one per-
son was hospitalized. The median estimated dose of
selenium consumed was 41749 μg/day. Frequently
reported symptoms included diarrhoea (78%), fatigue
(75%), hair loss (72%), joint pain (70%), nail discolora-
tion or brittleness (61%), and nausea (58%) [32]. It is
suggested that hair, fingernails and toenails may all act
as excretory organs when excess amounts of selenium
are ingested [33]. The Food and Nutrition Board-Insti-
tute of Medicine [34] fixed the highest daily level of
selenium that is likely to pose no risk of adverse health
effects in almost all individuals at 400 μg selenium per
day [31].
Compliance and drug accountability
The message of compliance is repeated during each fol-
low-up visit. Patients are encouraged to return unused
medication and empty packs. In order to check compli-
ance, the research nurse counts and records the remain-
ing unused tablets during each follow-up visit. Unused
medication is collected and destroyed by PharmaNord.
Data collection
Patients receive a self-completion questionnaire after
TUR, comprising questions about socio-demographics
(age, sex, ethnicity, marital status, education) health-
related lifestyle (lifetime smoking, history, passive smok-
ing), medical and drug history, dietary intake (food-type
frequency, alcohol, caffeine and total fluid intake, use of
vitamins), social support and quality of life. The quality-
of-life questions were developed by the European Orga-
nization for Research and Treatment for Cancer
(EORTC). Assessments using the general cancer ques-
tionnaire QLQ-C30 and the QLQ-BLS24, with 24 sup-
plemental questions, are made at baseline, after 6 and
36 months. A full version of the baseline and the fol-
low-up questionnaires is available as a free download at
http://www.bcpp.bham.ac.uk/seleblateng/patients.shtml.
Patients’ medical records are regularly examined by the
research nurses for information on clinical treatment,
histopathology, and outcome measures, which are
reported on case report forms.
Blood samples are collected at baseline. A research
nurse collects blood from all patients in a 5-mL EDTA
tube for selenium measurement and one plain 10-mL
tube for DNA-analysis. After the three-year intervention
period a new blood sample for selenium measurement is
collected.
Adverse event and serious adverse event monitoring
strategy
For the purpose of this trial, any detrimental change in
the patient’s condition subsequent to the start of trial
treatment and during the trial follow-up period, which
is not unequivocally due to the underlying disease pro-
cess of bladder cancer, is considered as either an adverse
event (AE) or a serious adverse event (SAE). Adverse
events and serious adverse events are being monitored
during and between regular follow-up visits in accor-
dance with the legal regulations.
Statistical analysis
Final statistical analysis is on an intention-to-treat
basis. Kaplan-Meier estimates of a recurrence-free
interval are used to compare treatment groups descrip-
tively, whilst log-rank tests are used to test the hypoth-
esis of no difference between treatments. Cox
proportional hazards regression models are used to
estimate the Hazard risks and 95% confidence intervals
comparing patients randomized to active selenium ver-
sus placebo with and without adjustment for age, sex
and stage at time of diagnosis. A per protocol analysis
will be performed as a sensitivity analysis. We will also
test for interactions with possible additional effect
modifiers such as smoking, selenium at baseline as an
indicator of selenium intake. For secondary outcome
measures, treatment arms are compared in terms of
progression-free interval using Kaplan-Meier and log-
rank tests. The reasons for excluding patients from the
analysis are clearly reported.
All analyzes are performed using STATA (StataCorp.
2009. Stata Statistical Software: Release 11. College Sta-
tion, TX: StataCorp LP)
Sample size calculations
Sample size calculations are based on the recent meta-
analysis (N = 2820) by Malström et al. [35] who looked
at the recurrence after standard treatment (instillations
of mitomycine or BCG). This is the group that corre-
sponds best with our placebo-group (standard care).
T h ea b s o l u t ed i f f e r e n c eb e t w e e nt h ep l a c e b o -a n dt h e
Selenium-group is based on the difference in percent of
recurrence after five years (average of time after rando-
mization in our study). A difference of 12,5% in absolute
reduction can be expected, considering that the intake
of 200 μg of SelenoPrecise yeast increases the plasma
selenium by ± 100 ng/mL [29] and that, according to
epidemiological studies, the incidence of bladder cancer
decreases by 25% if the plasma selenium increases by 10
ng/mL [10].
To detect an absolute decrease of 12,5% in the recur-
rence-free rate by selenium versus placebo, 700 patients
are needed, taking into account a drop out of 25% with
a power of 86% (two-sided test).
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An independent data and safety monitoring board will
periodically review the efficacy and safety data. Two for-
mal interim analyses of efficacy will be performed as
soon as the first 100 patients have reached one and two
years after randomization. The interim analyses will
enable the study to be stopped early if a clear result
should emerge. This will take place if a statistically sig-
nificant increase or decrease in recurrence rate of at
least 10% has been found.
Baseline characteristics
At the time of writing we have recruited 177 patients.
After one year of recruitment, 137 patients were
assessed for eligibility of which 100 met the inclusion
criteria. All patients were between 46 and 88 years and
their mean age was 68 (± 9) years. Eighty-three percent
of the patients were male and 87% of them Dutch-
speaking. Sixty percent had a primary tumour and 60%
had a solitary tumour. Seventy-nine percent of the
tumours were papillary. The baseline plasma selenium
was 84.8 ng/mL (± 18.5 ng/mL). Baseline characteristics
were summarized in Table 1.
Discussion
This is the first report of a trial in tertiary prevention of
selenium for bladder cancer. Other chemopreventive
trials have been performed [24,36]. High dose vitamins
improved significantly the time to tumour recurrence (p
= 0.0014) [37]. Retinoids have been tested with various
results [38-40]. Neither vitamin B6 (Pyridoxine) [41,42]
nor difluoromethylornithine reduced the rate of recur-
rence [43]. Lactobacillus casei powder significantly
reduced the time to recurrence in the intervention
group [44,45]. Several ongoing trials are investigating
cyclooxygenase-2 inhibitors in the recurrence of bladder
cancer. Preliminary analysis of the results of the study
based at the MD Anderson Cancer Center did not
d e m o n s t r a t ead i f f e r e n c ei nt i m et ot u m o u rr e c u r r e n c e
between the two treatment arms [24]. We are aware of
one other selenium and vitamin E factorial trial (SELE-
NIB) that is currently recruiting in the UK [46]. This
chemoprevention study, which is largerly similar to our
study (as far as the selenium arm is concerned), aims to
include 500 patients with non muscle-invasive bladder
cancer. In this trial, patients receive a daily supplement
of 200 μg high selenium yeast or placebo and 154 mg
daily a-tocopherol or placebo for 5 years using a 2 × 2
factorial design. Two chemopreventive trials on prostate
cancer with selenium yeast are currently ongoing [47].
Selenized yeast was selected for use in this trial
because of its availability and well-characterized safety
profile. In both the SELECT trial (prostate cancer pre-
vention) and the NPC trial (basal cell or squamous cell
skin cancer prevention), selenium supplementation was
not significantly associated with any of the cardiovascu-
lar disease endpoints during 7.6 years of follow-up (all
cardiovascular diseases, myocardial infarction, stroke, all
cardiovascular disease mortality) [48]. In secondary ana-
l y s e so fd a t af r o mt h eN P Cs t u d y ,5 8s u b j e c t si nt h e
selenium-supplemented group (n = 600) and 39 subjects
in the placebo group (n = 602) developed type 2 dia-
betes (hazard ratio 1.55; 95% CI, 1.03-2.33) [49]. In the
SELECT trial a statistically non-significant increased risk
of type 2 diabetes was observed in the selenium group
(RR, 1.07; 99% CI, 0.94-1.22) but not in the selenium
vitamin E group [21]. A secondary analysis was carried
out using data from a pre-existing randomized clinical
trial designed to investigate the effects of selenium yeast
on prostate cancer progression (Watchful Waiting Trial)
[50]. There were no statistically significant differences in
glucose levels during the course of the trial in men sup-
plemented with selenium as compared with those on
Table 1 Baseline characteristics of randomized
participants in the SELEBLAT trial
Variable Total 100
Gender [N (%)] Male [N (%)] 83 (83)
Female 17 (17)
Age ≤ 50 yrs. [N (%)] 2 (2)
51-60 [N (%)] 17 (17)
61-70 [N (%)] 34 (34)
71-80 [N (%)] 36 (36)
> 80 [N (%)] 11 (11)
Years [mean, (SD)] 68 (9)
Language [N (%)] Dutch 87 (87)
French 13 (13)
Primary Primary 61 (60)
Tumour [N (%)] Recurrent 35 (35)
Unknown 5 (5)
Tumour G1 31 (30)
Grade [N (%)] G2 35 (34)
G3 33 (32)
Unknown 4 (4)
Tumour pTa 60 (58)
Stage [N (%)] pT1 31 (30)
Cis 5 (5)
Unknown 7 (7)
Tumour Papillary 121 (79)
Type [N (%)] Cis 29 (19)
Unknown 3 (2)
Tumour < 1 cm 59 (38)
Size [N (%)] ≥1 and ≤ 3 56 (37)
> 3 cm 38 (25)
Tumour Solitary 59 (60)
Number [N (%)] 2 or more 36 (36)
Unknown 4 (4)
Selenium ng/mL [mean, (SD)] 84.8 (18.5)
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serum selenium concentrations were associated with
higher prevalence of diabetes and higher fasting plasma
glucose and glycosylated hemoglobin levels. Mean
serum selenium level in this trial was 137.1 ng/mL [51].
In the New England case-control study, independently
of the selenium serum level, an increase bladder cancer
risk was associated with a history of diabetes (adjusted
odds ratio = 2.2, 95% CI, 1.3 to 3.8). The risk may be
greater among patients taking oral hypoglycemics and
those with diabetes of longer duration [52]. Total cho-
lesterol, triglycerides, LDL cholesterol, and fasting
serum glucose concentrations significantly increased
with serum selenium concentration in the Taiwanese
elderly. The mean serum selenium concentration was
89.76 ng/mL [53]. In the UK, the PRECISE Pilot trial
randomized 501 elderly volunteers of relatively low sele-
nium status [mean (SD) plasma selenium 88.8 (19.2 ng/
mL)] to a six-month treatment with 100, 200 or 300 mg
selenium/day as high-selenium yeast or placebo yeast
[36]. Supplementation at 100 and 200 mg selenium/day
lowered total serum cholesterol and non-HDL choles-
terol [54]. The effects of a long-term selenium supple-
ment on blood pressure are inconsistent. Laclaustra et
al. reported that blood pressure increases if the plasma
selenium level is higher than 160 ng/mL [55]. In a
cross-sectional study with selenium in Belgium, the
Flemish Study on Environment Genes and Health Out-
comes (FLEMENGHO), 20 ng/mL higher plasma sele-
nium level was associated with a clinically not relevant
lower blood pressure with an effect sizes of 2.2 mmHg
systolic (95% CI -0.57 to -5.05; p = 0.009) and 1.5
mmHg diastolic (95% CI -0.56 to -2.44; p = 0.017) in
men, but not in women [56]. As in Belgium the daily
intake of selenium is low, we think that patients taking
selenium for three years can only benefit from this treat-
ment, including of blood pressure reduction.
If it is possible to increase the time to recurrence with
selenium, patients have to undergo fewer cystopscopies.
This means a reduction not only in suffering for the
patient, but also in costs for society.
We are aware that the selenium status at baseline and
the genetic variation of tested individuals may represent
additional reasons for positive or negative results [8] or
risk of disease [54]. There are 25 selenoproteins and
three selenium-containing enzymes (glutathione peroxi-
dases, thioredoxin reductases and iodothyronine deiodi-
nases), the first two being linked with antioxidant
activity, and the latter involved with thyroid hormone
metabolism. Rayman [57] suggests that only those per-
sons at risk, those with single nucleotide polymorphisms
in selenoproteins, GPx1, GPx4, SEPS1, Sep15, SEPP1
and TXNRD1, should be treated with selenium at doses
which optimize the plasma selenium levels in order to
activate specific selenoproteins. An intake of 40 μgp e r
day is required to maintain the plasma glutathione per-
oxidase (GPx) activity at plateau [58]. We will be inves-
tigating those additional genetic analyses in a
subsequent sub-project.
The SELEBLAT study is well-designed. Selenium-yeast
is a safe and cheap medicine. A computerized program
performs our randomization. Neither the investigators,
nor the research nurses have access to the randomiza-
tion numbers. All study personnel is blinded for the
medication. Both treatment groups are regularly com-
pared on similarity of prognostic characteristics such as
age, gender, smoking, grade of tumour, baseline sele-
nium level and co-morbidity. We will report reasons
and numbers of those patients lost to follow up. Both
an intention to treat and a per protocol analysis will be
performed. For hypothesis building subgroup analyses
and analyses of interactions will be performed, as we
have demographic and clinical data and questionnaires
results on diet and Quality of Life. Standard treatment
will be compared between the intervention and the pla-
cebo group. Additional intake of selenium by food sup-
plements will be analyzed and compliance will be
reported. Our primary outcome measures are both clini-
cal and histologically confirmed recurrences as fre-
quently patients with clinical recurrence are only
cauterized without taking a biopsy. Cauterization only
reduces the risk of perforation of the bladder. All subse-
quent patients undergoing TUR operation are included
meeting the inclusion criteria. We decided to include
both primary and second primary tumours, because the
incidence of bladder cancer is low, while the prevalence
and the rate of tumour recurrence is high [24]. Recur-
rence within the first three months after TUR is consid-
ered as residual untreated disease. Although bladder
cancer and prostate cancer occur together in 10% of the
cases [59,60], we decided to exclude patients with pros-
tate cancer too. We deliberately did not exclude any
patient for presence of co-morbidity or age aiming for a
study population, which represents as far as possible the
normal population diagnosed with bladder cancer. We
intend to reach the calculated sample size by pooling of
our results with the results from the Selenib study (UK),
which is similar in design. Progress of the study can be
followed on the website: http://www.genepid.bham.ac.
uk/Seleblat_Recruitment.shtml. The first results of our
study can be expected for 2014.
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